Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity

Targeted covalent drugs of the kinase family

(2010) Juswinder Singh et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia

(2009) R. Crazzolara et al.   BLOOD

Tyrosine kinases and their substrates in B lymphocytes

(2009) Tomohiro Kurosaki et al.   IMMUNOLOGICAL REVIEWS

BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3

(2008) J. Nakayama et al.   BLOOD

Bone Marrow X Kinase-Mediated Signal Transduction in Irradiated Vascular Endothelium

(2008) T. Tu et al.   CANCER RESEARCH

Chemokine CXCL12 enhances proliferation in pre-B-ALL via STAT5 activation

(2007) Frida Mowafi et al.   PEDIATRIC BLOOD & CANCER